Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hepatic arterial embolisation with irinotecan versus systemic FOLFIRI in patients with liver metastases from colorectal cancer

X
Trial Profile

Hepatic arterial embolisation with irinotecan versus systemic FOLFIRI in patients with liver metastases from colorectal cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irinotecan (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer; Liver metastases
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 21 Jan 2012 Results presented at the 2012 Gastrointestinal Cancers Symposium.
    • 12 Oct 2010 Updated 24-month results (n=74) presented at the 35th Congress of the European Society for Medical Oncology
    • 27 Jun 2009 Interim 18-month primary endpoint results presented at the 11th World Congress on Gastrointestinal Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top